Sobrera Pharma — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Sobrera Pharma is a clinical-stage biotech targeting the large, underserved market of Alcohol Use Disorder with a novel combination therapy of varenicline and bupropion. The company has successfully completed a Phase II trial showing statistically significant reductions in alcohol consumption, positioning it for potential Phase III development. As a private company, Sobrera is advancing its lead program while seeking partnerships and funding to address a significant global health burden.

Alcohol Use DisorderAddiction

Technology Platform

Proprietary fixed-dose combination of repurposed drugs (varenicline and bupropion) targeting dopamine deficit in the brain's reward pathway to reduce alcohol craving and consumption.

Opportunities

The global Alcohol Use Disorder market represents a multi-billion dollar opportunity with high unmet need due to limited and underutilized pharmacotherapy options.

Positive Phase II data and a clear mechanistic rationale position Sobrera to attract partnership interest from larger pharma companies with CNS expertise, providing a path to late-stage development and commercialization.

Risk Factors

Key risks include the inherent uncertainty of Phase III trial outcomes and regulatory approval for a combination therapy.

As a pre-revenue, single-asset company, Sobrera is highly dependent on securing a major partnership for development and commercialization, and faces competition from both existing therapies and new modalities entering the addiction space.

Competitive Landscape

Sobrera competes in the AUD pharmacotherapy market against established drugs like naltrexone, acamprosate, and disulfiram, as well as newer agents like topiramate. Its combination approach seeks to differentiate on efficacy. It also faces potential competition from other biotechs developing novel mechanisms (e.g., psychedelics, other neuromodulators) for addiction treatment.

More companies in Sweden →